Delayed Introduction of Everolimus in De Novo Renal Transplanted Patients: A Single-Center Experience.
Transplant Proc
; 48(2): 326-8, 2016 Mar.
Article
en En
| MEDLINE
| ID: mdl-27109947
ABSTRACT
INTRODUCTION:
Immunosuppressive protocols containing everolimus (EVR) preserve good renal function in kidney transplantation (KT), although they are often complicated by several adverse events. We have evaluated the efficacy and safety of a protocol with late (1 month after KT) EVR introduction. MATERIAL ANDMETHODS:
This study randomized 49 de novo patients undergoing KT between September 2012 and June 2014 into 2 groups group A (n = 24) with late EVR introduction and tacrolimus reduction, and group B (control group; n = 25) with a standard immunosuppressive regimen. Primary aims were 1-year patient and graft survivals and acute rejection rates. Secondary aims were related to wound, metabolic, and hematologic complications.RESULTS:
Patient and graft survivals were similar in both groups. One year after KT, median serum creatinine was inferior in group A (1.4 vs 1.8 mg/dL; P = .004). Late acute rejection (8.3 vs 12.0%; P = 1.0) and wound complication (4.2 vs 4.0%; P = 1.0) rates were similar. Higher cholesterol and triglycerides and lower platelets and hemoglobin levels were observed in group A.CONCLUSIONS:
In our experience, delayed introduction of EVR shows similar results with respect to its early introduction, contemporaneously presenting fewer wound complications and lymphoceles. A higher rate of metabolic and hematologic complications are, however, observed in patients under EVR therapy. Further multicenter studies should be performed to confirm these preliminary results.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Complicaciones Posoperatorias
/
Trasplante de Riñón
/
Everolimus
/
Supervivencia de Injerto
/
Inmunosupresores
Tipo de estudio:
Clinical_trials
/
Guideline
Idioma:
En
Revista:
Transplant Proc
Año:
2016
Tipo del documento:
Article